## PATENT COOPERATION TREATY

**PCT** 

REC'D 2 6 SEP 2005 WIPO

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)					
applicant's or agent's file reference	FOR FURTHER ACTION	[	See Form PCT/IPEA/416		
'30089	International filing date (day	/month/year)	Priority date (day/month/year)		
nternational application No. International riling da 8 October 2004			9 October 2003		
nternational Patent Classification (IPC)	or national classification and IPC	С			
nternational Patent Classification (200)	5/06, 005/08, A61K 035/39, 03	5/407, A61P 0	05/48, 035/00		
nt. Cl. 7 C07K 002/00, C12N 005	700, 003/08, 110111 030/07, 11				
Applicant MONASH UNIVERSITY et	al				
<ol> <li>This report is the international prelix Authority under Article 35 and trans</li> <li>This REPORT consists of a total of</li> </ol>	Similed to the approans account		ernational Preliminary Examining		
2. This REPORT consists of a total of	ANDTEVES comprising:		}		
3. This report is also accompanied by	to the International Bureau) a total	al of sheets, as	follows:		
sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).  Sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.  b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing					
Relating to Sequence List	ing (see Section 802 of the Admi	nistrative instruc	itions).		
4. This report contains indications re					
X Box No. I Basis of the	e report .		·		
Box No. II Priority  X Box No. III Priority  Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Box No. IV Lack of un	ity of invention	h regard to novel	ty, inventive step or industrial applicability;		
Box No. IV  Eack of unity of invention  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;  Citations and explanations supporting such statement					
	cuments cited				
Box No. VII Certain de	·				
X   Box No. VIII Certain observations on the international application					
	D	ate of completion	of the report		
Date of submission of the demand	. 14	4 September 20	05		
5 August 2005  Name and mailing address of the IPEA/	AU	uthorized Officer			
ATTORN ATTANDATION OFFICE	i i	25 Jourd			
PO BOX 200 WODEN ACT 2000, A	USTRALIA Í	AN DOWD	2) (202 2072		
E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Т	elephone No. (0	2) 0283 2213		

International application No.

PCT/AU2004/001376

lox.	No. I	Bas	s of the report			
	With reg	gard to the	e language, this report is based on the international application in the language in which it was med, unless sed under this item.			
	The wh	is report iich is th	is based on translations from the original language into the following language , e language of a translation furnished for the purposes of:			
		inter	international search (under Rules 12.3 and 23.1 (b))			
		publication of the international application (under Rule 12.4)				
	Г	inte	international preliminary examination (under Rules 55.2 and/or 55.3)			
<u>?</u> .	furnishe filed" a	th regard to the elements of the international application, this report is based on (replacement sheets which have been the regard to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally and are not annexed to this report):				
	ш		tional application as originally filed/furnished			
	. the	e descrip	tion:			
		-	pages as originally filed/furnished pages* received by this Authority on with the letter of			
			pages* received by this Authority on with the letter of pages* received by this Authority on with the letter of			
	☐ th	ne claims				
	Ш		pages as originally filed/furnished			
			pages* as amended (together with any statement) under Article 19			
			pages* received by this Authority on with the letter of			
			pages* received by this Authority on with the letter of			
	tł	he drawi				
			pages as originally filed/furnished pages* received by this Authority on with the letter of			
	٠		pages* received by this Authority on with the letter of pages* received by this Authority on with the letter of			
	а	segueno	e listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.			
3.	L		ndments have resulted in the cancellation of:			
	L	П	the description, pages			
	the claims, Nos.					
	the drawings, sheets/figs					
			the sequence listing (specify):			
		믐	any table(s) related to the sequence listing (specify):			
4.		This rep made, si 70.2(c))	ort has been established as if (some of) the amendments annexed to this report and listed below had not been not they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule			
			the description, pages			
		뉘	the claims, Nos.			
		님	the drawings, sheets/figs			
		님	the sequence listing (specify):			
			any table(s) related to the sequence listing (specify):			
		Ш	any money, remarks and a second a second and			
4	* If item 4 applies, some or all of those sheets may be marked "superseded."					

International application No.

PCT/AU2004/001376

Bo	k No.		
1.	The o	questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be strially applicable have not been examined in respect of:	
		the entire international application	
	X	claims Nos: 10-12, 23, 26-31, 35-40, 85-92, 95-101	
	bec	ause:	
		the said international application, or the said claims Nos.	l
		relate to the following subject matter which does not require an international preliminary examination (specify):	
		$\cdot$	
		<u>.</u>	
		the description, claims or drawings (indicate particular elements below) or said claims Nos.	
		are so unclear that no meaningful opinion could be formed (specify):	
	,		
	<u> </u>	the claims, or said claims Nos.	
	<u> </u>	are so inadequately supported by the description that no meaningful opinion could be formed.	
	X	- Nos. 10-12 23 26-31 35-40 85-92 95-101	
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the	
	L	Administrative Instructions in that:	
		the written form has not been furnished does not comply with the standard	
		the computer readable form has not been furnished  does not comply with the standard	
			y
		the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comple with the technical requirements provided for in Annex C-bis of the Administrative Instructions.	
		See Supplemental Box for further details.	_

International application No. PCT/AU2004/001376

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement						
Novelty (N)	Claims 1-9, 13-22, 24-25, 32-34, 41-84, 93-94, 102-103	YES				
•	Claims	NO				
Inventive step (IS)	Claims 1-9, 13-22, 24-25, 32-34, 41-84, 93-94, 102-103	YES				
•	Claims	NO				
Industrial applicability (IA)	Claims 1-9, 13-22, 24-25, 32-34, 41-84, 93-94, 102-103	YES				
	Claims	NO				

#### 2. Citations and explanations (Rule 70.7)

This report is based on the documents cited in the International Search Report:

D1 WO 2003 040355

D2 Differentiation. 1988 Dec;39(2):139-49

Novelty and Inventive Step

D1 discloses GCTM-1, -2, -3 and -4 antigen expression from human testicular teratomas. D2 relates to a sub-population of human embryonic stem cells (HES) that have markers for GCTM-2 antigen. Neither D1 or D2 disclose GCTM-5 antibody that binds to a cell marker. The application is therefore considered to be novel. The person skilled in the art would not be lead to GCTM-5 cell marker given the presence of a related, but different, GCTM-2 marker. Therefore, the application is considered to involve an inventive step.

Industrial Applicability

All claims satisfy the requirements of industrial applicability.

International application No.

PCT/AU2004/001376

#### 30x No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 10-12, 23, 26-31, 35-40, 85-92, 95-101 are indefinite in scope and go beyond the invention as described. The inventive concept resides in the cell marker binding to a GCTM-5 antibody or active fragment thereof. The above claims are not so limited to this particular antibody. For instance, claim 10 defines a detector which identifies on the cell type a cell marker, but this marker may or may not be the same as the GCTM-5 antibody. Similar reasons apply for the remaining claims.